Hemostemix Announces Convertible Debenture Financing.
CALGARY, Alberta, Canada, April 15, 2019 -- Blood-derived stem cell therapy company Hemostemix Inc., (OTCQB: HMTXF) said that it intends to complete a non-brokered private placement of $6 million secured convertible debentures.
Each debenture will consist of $1,000 aggregate principal amount of 8 percent secured, non-transferable, convertible, redeemable debentures. The debentures will mature twenty-four months from the date of issuance with interest at eight percent a year.
The proceeds of the debenture offering will be used to continue to fund the company's phase 2 trial for CLI, research and development, costs towards other clinical trials including application for an angina pectoris trial and for general working capital.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Finance & Funding|
|Publication:||Stem Cell Business News|
|Date:||Apr 29, 2019|
|Previous Article:||Osiris Acquisition By Smith & Nephew Plc Closes.|
|Next Article:||ThermoGenesis Releases Enhanced X-MINI CD3 Selection Kit For Researchers.|